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Zusammenfassung
Myelodysplastische Syndrome (MDS) sind eine hetero-
gene Gruppe von Erkrankungen, die hauptsächlich ältere
Menschen betreffen. Welche der inzwischen verfügbaren
therapeutischen Optionen eingesetzt werden sollte,
hängt von einer systematischen Risikostratifizierung der
Patienten ab. Ein hoher Prozentsatz von MDS-Patienten
benötigt Bluttransfusionen als unterstützende Therapie,
welche die Lebensqualität beeinflussen und einen gro-
ßen Teil der Kosten der MDS-Therapie verursachen. Die-
ser Beitrag basiert auf einem Workshop mit dem Titel
«MDS – Burden of Disease» (Oktober 2006 in München),
und befasst sich mit der Erkrankung unter therapeuti-
schen, versorgungsrelevanten und gesundheitsökonomi-
schen Gesichtspunkten.
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Summary
Myelodysplastic syndromes (MDS) are a heterogeneous
group of diseases mainly affecting older people. The use
of an increasing number of therapeutic options depends
on a systematic risk stratification of the patients. A high
percentage of MDS patients need blood transfusions as
supportive care, which influence quality of life and cause
a great part of the costs generated by MDS therapy. In
this article which is based on a workshop about the bur-
den of MDS held in October 2006 in Munich, MDS is dis-
cussed with regard to different aspects: current thera-
pies, transfusion medicine, geriatrics, quality of life, and
health economic aspects. 
Introduction
Myelodysplastic syndromes (MDS) encompass different hema-
tological conditions characterized by chronic cytopenia (ane-
mia, thrombocytopenia, neutropenia) and abnormal cellular
maturation of hematopoiesis. Patients with MDS are at risk of
symptomatic anemia, bleeding complications, and infections
[1]. Another life-threatening factor is progression to acute
leukemia in approximately 20% of the patients, which is often
refractory to treatment compared to de novo acute myeloid
leukemia (AML) [2, 3]. MDS are clonal disorders of the
pluripotent hematopoietic stem cells resulting in different
forms of cytopenia of peripheral blood cells. The bone marrow
is at the same time hypercellular, normocellular, or, in rare
cases, hypocellular, and often shows morphological changes in
all cell lines. The contrast between peripheral blood cytopenia
on the one hand, and normal or increased bone marrow cellu-
larity on the other hand, is attributable to ineffective hemato-
poiesis, with a large proportion of precursor cells dying prema-
turely in the bone marrow. This mainly occurs through apopto-
sis. However, it is still unclear which intrinsic or external fac-
tors trigger the high rate of apoptosis. In more than 90% of
cases, the etiology of the disease is unknown. Secondary MDS
is linked to prior treatments with intensive chemo- or radio-
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therapy. Chromosomal alterations, especially deletions of genes
which are crucial for cell growth, differentiation, and signal
transduction in hematopoietic stem cells (e.g. on chromosomes
1, 5, 7, 11, 13, 20), play an important role [4]. 
There are no typical early symptoms of MDS. Patients present
with fatigue, petechial bleeding, or frequent infections due to
the different forms of cytopenia. However, in elderly patients
anemia and MDS are often diagnosed accidentally when pa-
tients are treated for a different disease. MDS is diagnosed by
morphological and cytochemical analysis of peripheral blood
and bone marrow, as well as cytogenetic and molecular biolog-
ical analysis of the bone marrow aspiration. Bone marrow
biopsy with immune histochemistry and immune phenotyping
of the aspiration by fluorescence-activated cell sorting (FACS)
are additional techniques. Other underlying causes resulting in
the clinical picture of MDS such as alcohol and drug abuse,
medication, or prior chemo- and or radiotherapy should be
sought. Furthermore, vitamin B12, folic acid, and copper defi-
ciency should be excluded [5, 6]. Patients with MDS have been
classified into subgroups according to the French-American-
British (FAB) consensus conference in 1982 [7]. The current
form of classification is a modification of the FAB consensus
by the World Health Organization (WHO) as shown in table 1.
Epidemiology and Risk Stratification
MDS are a relatively common hematological disorder. It is a
disease of elderly patients, and it is rarely found in adolescents
or young adults. The average age at diagnosis is between 65
and 70 years. The MDS registry at Düsseldorf has been col-
lecting patient data in Germany for a long time. Reviewing
this data base, an overall incidence of MDS of 5/100,000 in-
habitants per year was revealed. The incidence increases
rapidly in the older patient groups, and reaches 20–50 cases
per 100,000 inhabitants in the group older than 70 years. These
data are comparable to the estimated incidence in the indus-
trialized world. Men develop MDS slightly more often than
women and are even predominant in the older patient groups.
Although the incidence in different age groups did not change
when surveying a longer period of time, the future will bring
an increase in the total number of MDS patients. The major
contributing factor is the ‘graying society’, the increasing aver-
age age in the populations of the western world. Improved di-
agnostics (cytogenetics and molecular biological techniques)
and a more precise diagnostic approach in anemic old or geri-
atric patients will possibly reveal formerly undefined MDS
 patients. Improvement and innovations in MDS therapy and
supportive therapy may lead to a prolonged lifetime of these
patients, linked with longer disease time and prolonged need
for transfusions. Furthermore, there might be an increase in
secondary MDS forms due to more aggressive chemothera-
pies in different malignant diseases. 
The FAB classification and the WHO standard helped to sys-
tematically classify this heterogeneous disease but were less
useful in determining the prognosis [8]. Reviewing the survival
data from previous reported studies, variables were consid-
ered in a new way to form the ‘International Prognostic Scor-
ing System’ (IPSS). The percentage of marrow blasts, specific
cytogenetic abnormalities, and the number of cytopenias were
used in combination to define 4 risk groups for overall sur-
vival and progression to AML: low, intermediate-1, intermedi-
Table 1. WHO classification of myelodysplastic syndromes (MDS) (based on [58])
Subtype Blood Bone marrow
Refractory anemia (RA) anemia; no or rare blasts erythroid dysplasia only, < 5% blasts; < 15% 
ringed sideroblasts
Refractory cytopenia with multilineage cytopenias (bicytopenia or pancytopenia); dysplasia in ≥ 10% of cells in ≥ 2 myeloid cell
dysplasia (RCMD) no or rare blasts; no Auer rods; < 1 × 109/l lines; < 5% blasts; no Auer rods; < 15% ringed 
monocytes sideroblasts 
Refractory anemia with ringed anemia, no blasts erythroid dysplasia only, < 5% blasts; ≥ 15% 
sideroblasts (RARS) ringed sideroblasts 
Refractory cytopenia with multilineage cytopenias (bicytopenia or pancytopenia); dysplasia in ≥ 10% of cells in ≥ 2 myeloid cell
dysplasia and ringed sideroblasts no or rare blasts; no Auer rods; lines; < 5% blasts; no Auer rods; ≥ 15% ringed
(RCMD-RS) < 1 × 109/l monocytes sideroblasts 
Refractory anemia with excess blasts-1 cytopenias; < 5% blasts, no Auer rods; unilineage or multilineage dysplasia; 5% to 9% 
(RAEB-1) < 1 × 109/l monocytes blasts; no Auer rods
Refractory anemia with excess blasts-2 cytopenias; 5–19% blasts; Auer rods ±; unilineage or multilineage dysplasia 10% to 19%
(RAEB-2) < 1 × 109/l monocytes blasts; Auer rods ± 
Myelodysplastic syndrome, unclassified cytopenias; no or rare blasts; no Auer rods unilineage dysplasia in granulocytes or
(MDS-U) megakaryocytes; < 5% blasts; no Auer rods
MDS associated with isolated del (5q) anemia; < 5% blasts; platelets normal or normal to increased megakaryocytes with
increased hypolobated nuclei; < 5% blasts; no Auer rods; 
isolated del (5q)
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ate-2, and high [9] (table 2a, b). The analysis of patient data
from the MDS registry in Düsseldorf showed an average sur-
vival time of between 7 and 62 months depending on the risk
stratification of the patients. On the basis of the collected data,
other prognostic variables such as the lactate dehydrogenase
(LDH) serum level were taken into account to develop the
Düsseldorf score for the prognostic determination of MDS
subgroups [10–12]. The Düsseldorf score (table 3) consists of 
3 risk groups: low (0 points), intermediate (1–2), and high
(3–4). The following 4 variables get 1 point if present: hemo-
globin level < 90 g/l, platelets < 100 G/l, LDH elevated, blasts
in marrow > 5%.
Due to a similar disease course and prognosis, patients with
high-risk MDS according to IPSS can be considered as already
having AML when it comes to treatment decisions. It is im-
portant to note that most patients with MDS, even those with
IPSS intermediate risk-2, will die due to bone marrow failure
rather than transformation to AML. 
Treatment Options in MDS
Due to the fact that MDS comprises a very heterogeneous
group of patients, treatment of MDS should be adjusted indi-
vidually to every patient. There are 4 major therapeutic goals:
control of symptoms caused by cytopenia, improvement of
quality of life, improvement of overall survival, and decrease
of progression towards AML [9]. The therapeutic approach
should be based mainly on 3 features: age, performance status,
and the IPSS-defined risk category [13].
Allogeneic hematopoietic stem cell transplantation (SCT) is
the only curative chance for patients with MDS. Due to the ag-
gressiveness of the treatment in the past, the age of the pa-
tient had to be below 60 years. New non-myeloablative regi-
mens extended the approach into the group of 60–70-year-old
patients. However, a lot of preconditions have to be fulfilled:
age, performance status, a matched donor, general health sta-
tus, and a risk group of intermediate-1 or higher. Only an esti-
mated 5% of MDS patients are eligible for this approach. De-
spite the curative chance, transplantation- and relapse-related
mortality is relatively high and results in a 5-year survival of
between 40 and 60% [14]. If no donor is available, in younger
patients at high risk, intensive chemotherapy according to an
AML protocol is an alternative to SCT. 
Supportive care is the central component for all MDS treat-
ments, and it is the only essential option for the majority of
the patients due to advanced age, comorbidities, and the
chronic course of MDS. Cytopenia, especially anemia, is one
of the major findings in MDS. At least 70% of patients will be-
come transfusion-dependent during the course of the disease.
If thrombocytopenic bleeding occurs, platelet transfusions are
needed. Patients should be treated with antibiotics for infec-
tion especially when neutropenic. Supportive care also com-
prises the treatment of other concomitant problems (e.g. heart
and lung disease).
Hematopoietic growth factors may be used in MDS, however, a
low or decreasing responsiveness is seen in a lot of cases; e.g.
recombinant human erythropoietin (EPO) alone leads to a re-
sponse rate (defined as increasing or stable hemoglobin con-
centration without the need for transfusion) of only 10–20% of
MDS patients [15]. However, the synergistic combination with
granulocyte colony-stimulating factor (G-CSF) leads to elevat-
ed response rates in defined patient subgroups, e.g. 70% in pa-
tients with low endogenous EPO levels (< 200 mU/ml), low
transfusion need, and an IPSS low or intermediate-1 [16–18].
Further, the Nordic MDS Group sees a potential benefit in
combining the two growth factors in the defined subgroups
[19]. One reason might be the change in the response criteria
(IWG2000 vs. IWG 2006), but further studies are needed.
Immunosuppressive drugs such as antithymocyte globulin
(ATG) and cyclosporine can be used in patients with hypocel-
lular bone marrow. In these patients, immune-mediated mar-
row suppression might play a major role in the etiology of the
disease [20–24].
Table 2a. International Prognostic Scoring System (IPSS): percentage of
marrow blasts, specific cytogenetic abnormalities, and number of cytope-
nias were used in combination to define 4 risk groups for overall survival
and progression to AML
Prognostic variable Survival and AML evolution – score value
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯
0 0.5 1.0 1.5 2.0
Marrow blasts, %a < 5 5–10 – 11–20 21–30
Karyotype good intermediate poor
Cytopenia 0/1 2/3
aPatients with 20–30% blasts may be considered as MDS or AML.
MDS = Myelodysplastic syndromes; AML = acute myeloid leukemia.
Table 2b. International Prognostic Scoring System (IPSS): resulting risk
groups [13, 59]
Risk category % of Score Median 25% AML
IPSS survival  progression
popula- in absence  in absence
tion of therapy, of therapy, 
years years
Low risk 33 0 5.7 9.4
Intermediate risk-1 38 0.5–1.0 3.5 3.3
Intermediate risk-2 22 1.5–2.0 1.2 1.1
High risk 7 > 2.5 0.4 0.2
AML = Acute myeloid leukemia.
Risk Patients, Survival, 
% months
Low 15 71
Intermediate 57 27
High 28 7
Table 3. Düsseldorf
score: patient
 distribution in risk
groups and survival
(n = 1,636)
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Thalidomide has been used as an antiangionetic immunomod-
ulatory drug with inconsistent effects, low response rates, and
severe side effects (e.g. fatigue, neuropathy) [25, 26]. Lenalido-
mide is an orally administered immunomodulatory derivative
of this substance without the typical side effects. In a phase II
study with transfusion-dependent, erythropoietin-refractory
patients, it has shown response rates of 56% (no transfusions
or reduction of more than 50%). Most of the patients had an
IPSS low or intermediate-1. The best results were seen in pa-
tients with del(5q), where even cytogenetic responses were
achieved [27, 28]. 
Low and intermediate intensity chemotherapeutic agents are
used in patients with intermediate or high IPSS. DNA methyl-
transferase (DNMT) inhibitors include azacitidine and decita-
bine. 5-azacitidine has been tested in a phase III trial and
showed 7% complete response (CR), 16% partial response
(PR), and hematological improvement in 36% of the patients
[29]. Decitabine showed an overall response rate of 17% (in-
cluding 9% CRs), and additionally 13% of hematological im-
provement in patients treated in a phase III trial. There was a
trend towards longer median time to progression to AML [30].
Both substances exert their antineoplastic effect by hypome-
thylation of DNA and direct toxicity on hematopoietic cells.
They are supposed to induce re-expression of tumor suppres-
sor genes. The substances are tested in further trials. Cytara-
bine plays a minor role due to low remission rates. 
New drugs have been introduced in trials and MDS therapy,
including arsenic trioxide, oral farnesyltransferase inhibitor,
inhibitors of tumor necrosis factor alpha, and anti-angiogene-
sis agents such as anti-VEGF as well as histone deacetylase
(HDAC) inhibitors such as valproic acid [31, 32]. 
Several new drugs have been developed for the treatment of
MDS, however, not all are yet approved in Europe for this indi-
cation. Although clinical trials could show promising results, fur-
ther studies have to be conducted to show the long-term benefits
regarding response rates, overall survival, and quality of life, as
well as potential adverse effects and cost effectiveness.
Transfusion Medicine Focusing on MDS
Patients with MDS are a challenge for transfusion medicine.
The previous chapter has shown that cytopenias are the result
of ineffective dysplastic hematopoiesis. The majority of these
patients need transfusions, especially of red blood cells
(RBC). To guarantee an optimal supply for transfusion-de-
pendent patients, a sufficient number of RBC units must be
stored at any time in the transfusion center. Calculating an av-
erage need of 24 RBC units per MDS patient per year [33],
the enormous need in this single patient group connected to
relevant costs becomes obvious. While the number of MDS
patients will increase in the next years, the supply of blood
products will become more difficult, because blood products
and donors are getting rare due to the demographic develop-
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ment. On the other hand, the aging population needs more
transfusions, not only in MDS but in other chronic diseases
and for surgical procedures. Since blood cannot be synthesized
in the laboratory (yet), blood products remain ‘special goods’,
and the indication for every single transfusion should be
checked carefully. Consequently, from a general point of view,
in transfusion medicine every therapy minimizing the need for
transfusion in a certain indication is important to minimize the
transfusion-related risks for the patient on one side, and on
the other side to save valuable provisions of blood as an
(emergency) supply for other patients.
Iron Overload
The safety of blood products has been increased over the past.
In addition, leukoreduction combined with irradiation of the
depleted product helped to minimize leukocyte-mediated
complications of transfusions such as febrile transfusion reac-
tions, platelet isosensitization, viral infections, and immuno-
suppression (even though irradiated erythrocyte concentrates
are not recommended for MDS patients in general [34]).
However, the iron overload in transfusion-dependent patients
is one problem of the supportive therapy which cannot be
abolished. The iron overload results in secondary hemochro-
matosis which can cause cardiac, hepatic, and endocrine mal-
functions. Patients with an expected prolonged transfusion
need, especially those with an IPSS low or intermediate-1,
should be considered for iron chelation therapy [35]. In high-
risk patients, the benefit will be minimal due to their short sur-
vival time. A serum ferritin level of > 1,000 μg/l, a high trans-
fusion rate, and the expected duration of transfusion need are
important parameters for the decision about treatment with
iron chelators. Deferasirox, an easily applicable oral chelation
therapy, is now available. It may be difficult to compare sur-
vival in patients with or without chelation therapy, since the
relationship between iron overload, high ferritin, RBC trans-
fusions, and shorter survival is not completely understood.
Generally, it can be stated that long-term RBC transfusion has
a negative effect on quality of life and survival in MDS
 patients [36].
MDS in Germany and Transfusion Dependency
Based on the data from a literature review, approximately
50% of MDS patients are transfusion-dependent across all
risk groups [37]. In Germany, between 3,800 and 5,400 MDS
patients needed transfusions in 2005. The number will increase
due to an estimated increase in the number of MDS patients
of approximately 6% per year. By the year 2010, the disease
will occur in between 10,000 and 14,000 patients. Table 4 cor-
relates the transfusion dependency of MDS patients in Ger-
many with their IPSS score. Due to the lack of published
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prevalence data for Germany, a lower [38] and a higher sce-
nario [39] of patient numbers were calculated.
MDS and Geriatric Medicine
The elderly people in a population are a very heterogeneous
group sharing the common features of a reduced life ex-
pectancy and reduced physiological organ function. The func-
tional abilities are decreasing whereas the number of comor-
bidities is increasing with higher age. This results in different
medications for different diseases, leading to a variety of phar-
macodynamic and pharmacokinetic changes. Anemia, the un-
specific finding at the beginning of a diagnostic process, is
often incidentally diagnosed in routine blood tests. The preva-
lence of anemia is increasing with age: 8% of the people older
than 65 years and 15–20% of those in the group older than 85
years are anemic. A variety of studies identified anemia as risk
factor for mortality [40–44]. Not only is the prevalence of ane-
mia increased in older age groups, but the risk for developing
a malignant disease increases as well [45]. A study from a geri-
atric department has shown that in 5% of elderly patients with
anemia, MDS is the underlying disease [46]: ‘early forms’ of
MDS such as refractory anemia (RA) and refractory cytope-
nia with multilineage dysplasia (RMCD) are those predomi-
nant in geriatric patients [47]. Generally, anemia is a frequent
finding in geriatric patients. A sufficient search for the cause is
not always undertaken, so the number of MDS cases is actual-
ly probably underdiagnosed. This group of patients is not well
studied, and literature describing outcome and quality of life is
not available.
Risk group MDS patients Transfusion-dependent MDS patients
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯
Patients,  Scenario 1: Scenario 2: Patients, Scenario 1: Scenario 2:
% [13] patients, n patients, n mean n [37] patients, n patients, n
Low 33 2,423 3,465 39 945 1,351
Int-1 38 2,790 3,990 50 1,395 1,995
Int-2 22 1,615 2,310 63 1,018 1,455
High 7 514 735 79 406 581
Total 100 7,343 10,500 51a 3,764 5,382
aWeighted average in % of transfusion-dependent MDS patients considering all risk groups;
source: calculations by the Medical Economics Research Group (MERG), Munich, Germany.
MDS = Myelodysplastic syndromes; Int = intermediate.
Table 4. MDS patients in Germany according
to risk score and transfusion dependency; 
due to lack of published prevalence data for
Germany, a lower [38] (scenario 1) and a higher
scenario [39] (scenario 2) of patient numbers
were calculated
Table 5. Quality of life studies in myelodysplastic syndrome patients 
Authors, year [Ref.] Country Study type Sample Data source/methods Results
size
Caocci et al., 2006 [49] Italy cross-sectional 33 QLQ-C30 QoL can be improved by lowering the amplitude 
of hemoglobin fluctuations
Stasi et al., 2005 [50] Italy phase II study 53 LASA FACT-AN statistically significant correlation between 
increased hemoglobin levels and increased QoL 
for the responder group
Oliva et al., 2005 [51] Italy cross-sectional 39 Specific questionnaire QoL in MDS patients is influenced by transfusion
QOL-E dependency
Casadevall et al., France randomized 60 FACT-AN QoL did not improve significantly under rHuE
2004 [15] clinical trial PO + RHuG-CSF
Clavio et al., 2004 [52] Italy prospective, open- 11 FACT-AN erythroid response appeared to be clinically
label, unicentric, correlated with the improvement of QoL: higher
non-randomized hemoglobin levels increased QoL
Spiriti et al., 2004 [53] Italy open-label, 133 FACT-AN QoL did improve under treatment with EPO
prospective, 
multicenter trial
Hellstrom-Lindberg Sweden decision model 63 QLQ-C30 QoL did improve significantly under treatment
et al., 2003 [17]
Jansen et al., 2003 [54] The Ne- cross-sectional 50 SF36 MFI Euro QoL- the 3 internationally established methods proved 
therlands 5D VAS to be useful in describing HRQoL in MDS patients
QoL = Quality of life; MDS = myelodysplastic syndromes; EPO = erythropoietin; rHuEPO = recombinant human erythropoietin;  
RHuG-CSF = recombinant human granulocyte colony-stimulating factor; HRQoL = health-related quality of life.
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Focusing on Inpatient and Outpatient Treatment of
MDS in Germany
Patients with either an unclear anemia or a supposed or al-
ready diagnosed MDS should be treated by a specialist for
hematology and oncology. The therapy often requires cooper-
ation between in- and outpatient departments for hematol-
ogy/oncology at hospitals and hematologists in office-based
practices. 
As described earlier, patients often present with unspecific
symptoms, or anemia is diagnosed in a routine blood analysis.
A profound disease history and clinical examination is fol-
lowed by a blood analysis. Different causes of anemia must be
excluded; a bone marrow aspiration including a cytogenetic
examination helps to find the diagnosis. If MDS has been di-
agnosed, the patient has to be risk stratified with IPSS, age,
and performance status, and has to be informed about possible
therapeutic strategies. Regarding the chronicity of the disease
and the often limited life expectancy in MDS, the primary goal
is to facilitate an outpatient treatment and minimize hospital
admissions. However, a patient diagnosed with advanced-stage
MDS spends 16% of his remaining life time in a hospital [48].
Red cell transfusions (RCT) and, if necessary, transfusion of
platelets can be given in the outpatient departments of hospi-
tals as well as in the office-based setting. The need for RCT is
not strictly defined by a certain hemoglobin level, but is relat-
ed to the subjective findings of the patient and dependents on
comorbidities (e.g. heart disease). Due to strict laws and
guidelines concerning the use and quality of blood products in
Germany, this best supportive care for MDS patients is con-
nected with high costs.
The Burden of MDS: Quality of Life and Health 
Economic Aspects
Existing quality of life studies in MDS patients use generic in-
struments due to the lack of a specially developed quality of
life questionnaire covering MDS (table 5). Two aspects seem
to be important for the quality of life of the patients: first, a
higher hemoglobin level, which means probably less fatigue
and a more active life; second, a decreased need for transfu-
sions, which means fewer visits to the doctors’ office and less
restrictions in daily life [15, 17, 49–54]. Results of health utility
interviews with MDS patients show that patients associate a
high hemoglobin value with achieving transfusion indepen-
dence, generating new health utility values to be used in eco-
nomic evaluations that compare the health outcomes of thera-
pies in quality-adjusted life years (QALYs) [55]. In elderly
compared to younger cancer patients, presence of anemia is
independently associated with poor quality of life in addition
to poor performance status [56]. However, a more interven-
Table 6. Cost studies of transfusion in myelodysplastic syndrome patients 
Authors, country, Type of study Scope Study Perspective Transfusion costs
year [ref.] population
Gupta et al., USA, retrospective to assess the costs and potential 50 male MDS hospital transfusion cost/patient/
1999 [57] record analysis complications of supportive patients year during MDS phase
(transfusion) care in MDS patients diagnosed US$ 1,614 (according to
between 1992 official procurement
and 1997 prices for American Red 
Cross blood products); 
US$ 4,877 (according to 
published average costs at 
US teaching hospitals)
Casadevall et al., clinical trial to evaluate health, costs, and 60 patients French treatment with rHuEPO +
France, 2004 [15] quality of life within 2 treatment with low-grade healthcare rHuG-CSF: I 6,200 trans-
groups of MDS patients MDS and serum payer and fusion cost and I 27,754
EPO levels lower  hospital total cost per patient; best
than 500 IU/l supportive care: I 7,148 
transfusion cost and I 7,846
total cost per patient  
Goss et al., USA, decision cost-effectiveness study with a transfusion- private payer annual cost per patient
2006 [60] analytic model 1-year time horizon; comparison dependent in the US under lenalidomide treat-
of lenalidomide with BSC without MDS patients ment: US$ 7,574 transfusion
EPO vs. BSC with EPO cost and US$ 63,385 total 
treatment cost; under 
supportive care: US$ 18,101
transfusion cost and US$ 
54,940 total treatment cost
MDS = Myelodysplastic syndromes; EPO = erythropoietin; rHuEPO = recombinant human erythropoietin; RHuG-CSF = recombinant human granu-
locyte colony-stimulating factor; BSC = best supportive care.
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tions with antibiotics and antifungal medication); iv) hemato-
poietic stem cell and bone marrow transplantation; v) inten-
sive and intermediate chemotherapy and its side effects; vi)
treatment of unwanted side effects of the primary interven-
tion; vii) influence of MDS and its therapy on comorbidities
(e.g. cardiac, pulmonary, vascular disease). All these aspects
can only be realized in a complex economic model which does
currently not exist for MDS. It could be an important step for-
ward in optimizing the individual therapy of the patient, by
treating the disease effectively, reducing the need for support-
ive care (especially transfusions), and improving quality of life. 
In a second step, cost effectiveness or cost utility analysis
should be conducted, taking quality of life into account. These
tools help to identify the advantages (benefit/value) and the
disadvantages (costs) of a procedure in a defined period of
time monetarily or in relation to quality of life. The results,
such as costs per treatment or costs per QALY, can help deci-
sion makers, e.g. medical practitioners, hospital managers, or
sickness funds, to decide rationally on their limited resources.
Asking questions on effectiveness and using evaluation tools
do not contradict good quality medical care but must be 
seen as instruments for fairer resource allocation. Particularly
in oncology, innovative pharmacological treatment options
which might seem expensive at first glance often offer the only
chance to improve survival and quality of life of the patients.
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tion-specific research on quality of life of MDS patients is de-
manded to better meet patients’ needs in the future [13].
Table 6 summarizes the very few international studies analyz-
ing the costs of MDS, but focusing mainly on the direct costs
of anemia and transfusion dependency [15, 57]. An RCT for
an individual patient causes costs on every step of the produc-
tion chain: donation-related direct and indirect costs, expenses
for transportation and compatibility tests, costs for material
and staff during the transfusion itself, costs for administration
and organization of a transfusion medicine department, and
expenses for the ongoing improvement and the guarantee of
high quality standards. Adding up these costs, the current price
of an RBC unit in Germany is 85–150 Euros. Consequently,
the cost of RCTs for transfusion-dependent MDS patients in
Germany ranges approximately between 7.8 and 20 million
Euros per year, or from 1,500 to 5,300 Euros per patient and
year. Analyzing these expenses in detail will reveal that MDS
patients cause even more costs because of more frequent
transfusion-related complications [57]. Additionally, it has to
be taken into consideration that there are not only costs for
the blood units but also in- or outpatient costs depending on
hospitalization or ambulatory treatment for transfusions. 
Identifying the real costs of MDS is difficult due to the com-
plexity and heterogeneity of the disease. A first step should
be an MDS cost analysis, identifying the resources used and
the costs generated by MDS symptoms and therapies: i)
 anemia (including RCTs, adverse transfusion reactions and
complications, iron overload and chelating therapy, the he-
matopoietic growth factors rHuEpo and G-CSF); ii) thrombo-
cytopenia (therapy of bleeding complications and platelet
transfusions); iii) neutropenia (diagnosis and therapy of infec-
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